Safety needle firm Bio-Plexus reaps benefits from investment
This article was originally published in Clinica
The Cooper Companies' women's healthcare business CooperSurgical saw its third-quarter revenues rise 30% to $20m, up 23% in the year to date. During the quarter, the company decided to phase out its Cerveillance colposcopy system, largely because the company has chosen to consolidate its colposcopy development into Leise Medical, which it bought 2000 and which claims a world leadership position in colposcopy. In May, CooperSurgical bought private infertility company Ackrad Laboratories for $12m.